Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Franklin FTSE South Korea ETF (FLKR) vs BIO-TECHNE Corp (TECH) Price & Performance

Franklin FTSE South Korea ETFTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Franklin FTSE South Korea ETF vs BIO-TECHNE Corp — how do they compare? Franklin FTSE South Korea ETF trades at $58.12 (market cap $1.88B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 6× Franklin FTSE South Korea ETF's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Franklin FTSE South Korea ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Franklin FTSE South Korea ETF for 15 Days and BIO-TECHNE Corp for 63 Days on average.

FLKRTECH
Market Cap
$1.88B$11.37B
Volume
709,7753,153,511
Sector
Broad Market / FactorHealth
52-Week High
$72.25$72.61
52-Week Low
$27.09$43.31
Typical Hold Time
15 Days63 Days
Enterprise Value
—$11.40B
Dividend Yield
—0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Franklin FTSE South Korea ETF

No Aura AI signal available yet.

BIO-TECHNE Corp

TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.

Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Franklin FTSE South Korea ETF

Franklin FTSE South Korea ETF seeks to track an index of South Korean equities. The fund provides exposure to companies listed in South Korea across multiple sectors.

Read more on FLKR →

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH →